Replies to post #134 on Equity Field Notes from temporal sources

[DanWebzster]

KPTI read out Ph2b results that will warrant an NDA filing for selexinor, its treatment for penta-refractory multiple myeloma (MM)

The TAM for this treatment could produce up to $500mn in sales. MM is the third most common blood cancer in the U.S.

Selexinor's market advantage is that it is an oral treatment competing against for-the-most-part less safe treatments.

After these results, the company released plans to issue a $125mn stock offering.